Transcenta Holding Limited (6628.HK)
HKD 0.6
(0.0%)
HKD 0.6
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -136.39 Million CNY | 71.82% |
| 2022 | -483.99 Million CNY | 43.55% |
| 2021 | -857.31 Million CNY | -53.29% |
| 2020 | -559.29 Million CNY | -181.15% |
| 2019 | -198.92 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -29.58 Million CNY | 78.31% |
| 2024 Q2 | -29.58 Million CNY | 67.13% |
| 2023 Q4 | -136.39 Million CNY | 3.36% |
| 2023 Q1 | -323.64 Million CNY | 33.13% |
| 2023 Q3 | -141.14 Million CNY | 55.67% |
| 2023 Q2 | -318.41 Million CNY | 1.62% |
| 2023 FY | -136.39 Million CNY | 71.82% |
| 2022 FY | -483.99 Million CNY | 43.55% |
| 2022 Q4 | -483.99 Million CNY | 1.07% |
| 2022 Q3 | -489.23 Million CNY | 27.65% |
| 2022 Q2 | -676.22 Million CNY | 0.91% |
| 2022 Q1 | -682.44 Million CNY | 20.98% |
| 2021 FY | -857.31 Million CNY | -53.29% |
| 2021 Q4 | -863.58 Million CNY | 0.0% |
| 2021 Q3 | -863.58 Million CNY | -38.65% |
| 2021 Q2 | -622.84 Million CNY | 18.72% |
| 2021 Q1 | -766.33 Million CNY | -35.2% |
| 2020 Q1 | 458.1 Million CNY | 0.0% |
| 2020 FY | -559.29 Million CNY | -181.15% |
| 2020 Q4 | -566.79 Million CNY | 0.0% |
| 2020 Q3 | -566.79 Million CNY | 0.0% |
| 2019 FY | -198.92 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | -78.605% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 102.59% |